1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-08-16 am EDT
3865.00 JPY   -0.08%
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Receives DX Grand Prix 2022 Awards in Digital Transformation Stocks (DX Stocks) 2022

06/08/2022 | 07:46am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received DX Grand Prix 2022 Awards in 'Digital Transformation Stocks (DX Stocks) 2022' selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE). From among TSE-listed companies, 'DX Stocks' are designated to those companies, in each industrial category, that have established internal systems to promote digital transformation (DX) leading to increased corporate value, and have outstanding achievements in digital utilization. Chugai has been selected as a DX Stock for three consecutive years and received DX Grand Prix 2022 Awards as a leading company in DX implementation.

Thirty-three TSE-listed companies were selected in consideration of contribution to corporate value, and capability of DX realization. Chugai won the Grand Prix as a leading company in promoting DX as its growth strategy 'TOP I 2030' is well linked with 'CHUGAI DIGITAL VISION 2030,' the company's vision for promoting DX, and its achievements in a series of initiatives for drug discovery and manufacturing processes, as well as those for healthcare professionals and patients. These comprehensive efforts were highly evaluated.

'We are very pleased to win the Grand Prix this year. 2021 was the final year of the Phase 1 (Change our people & culture) of CHUGAI DIGITAL VISION 2030, which is our roadmap for 2030. We successfully achieved many outcomes in strengthening our foundation, including reforming our corporate culture and enhancing digital talent,' said Chugai's Executive Vice President and Head of Digital Transformation Unit, Satoko Shisai. 'We've shifted to the Phase 2 (Change our business) from this year. Aiming at innovative novel drug discovery (DxD3*) with digital technologies, which is central of our vision, we will further gear up for accelerating utilization of data, advancing platform for enhancing digital talent, promoting open innovation in digital technology, and others.'

DX for Drug Discovery and Development

In order to realize its goal of becoming a top innovator in the healthcare industry, Chugai formulated a growth strategy 'TOP I 2030,' which is consisted of two pillars of 'global first-class drug discovery' and a 'futuristic business model.' DX is positioned as one of the key drivers to achieve the target. In accelerating DX, Chugai is committed to transforming its business and providing healthcare solutions that will change society through three basic strategies of CHUGAI DIGITAL VISION 2030: 1) Strengthen the digital platform, 2) Optimize all value chains, and 3) Digital transformation for drug discovery and development.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.,

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.08% 3865 Delayed Quote.3.56%
ROCHE HOLDING AG -0.71% 315.65 Delayed Quote.-16.14%
All news about CHUGAI PHARMACEUTICAL CO., LTD
08/15CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 191 B 8 952 M 8 952 M
Net income 2022 347 B 2 609 M 2 609 M
Net cash 2022 518 B 3 895 M 3 895 M
P/E ratio 2022 18,3x
Yield 2022 2,06%
Capitalization 6 358 B 47 349 M 47 778 M
EV / Sales 2022 4,90x
EV / Sales 2023 5,38x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 865,00 JPY
Average target price 4 617,50 JPY
Spread / Average Target 19,5%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD3.56%47 815
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582